Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer

Journal of Clinical Oncology

Volumn 32, Issue 13, 2014, Pages 1287-1289

  Liu, Joyce F ^a   Cannistra, Stephen A ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; DRUG SAFETY; EDITORIAL; FEMALE; HUMAN; MAINTENANCE THERAPY; OVARY CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; NOTE; OVARY TUMOR; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 84902602472     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.7299     Document Type: Editorial

References (20)

1. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:5165-5171, 2007 (Pubitemid 350237599)
2. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007 (Pubitemid 350232248)
3. Pujade-Lauraine E, Hilpert F, Weber B, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302-1308, 2014
4. Stockler MR, Hilpert F, Friedlander M, et al: Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 32:1309-1316, 2014
5. Burger RA, Brady MF, Bookman MA, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473-2483, 2011
6. Perren TJ, Swart AM, Pfisterer J, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484-2496, 2011
7. Aghajanian C, Blank SV, Goff BA, et al: OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039-2045, 2012
8. Monk BJ, Huang HQ, Burger RA, et al: Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 128:573-578, 2013
9. Stark D, Nankivell M, Pujade-Lauraine E, et al: Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: Quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 14:236-243, 2013
10. Cannistra SA: Evaluating new regimens in recurrent ovarian cancer: How much evidence is good enough? J Clin Oncol 28:3101-3103, 2010
11. Rock EP, Scott JA, Kennedy DL, et al: Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products. J Natl Cancer Inst Monographs 37:27-30, 2007
12. Cannistra SA: Cancer of the ovary. N Engl J Med 351:2519-2529, 2004
13. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001 (Pubitemid 32642183)
14. Mutch DG, Orlando M, Goss T, et al: Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811-2818, 2007 (Pubitemid 47123191)
15. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997 (Pubitemid 27251118)
16. National Comprehensive Cancer Network: NCCN guidelines: Ovarian cancer. http://www.tri-kobe.org/nccn/guideline/gynecological/english/ovarian.pdf
17. National Institute for Health and Care Excellence: TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. http://guidance.nice.org.uk/TA284
18. National Institute for Health and Care Excellence: TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. http://guidance.nice.org.uk/TA285
19. European Medicines Agency: Avastin. http://www.ema.europa.eu
20. Cohn DE, Kim KH, Resnick KE, et al: At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 29:1247-1251, 2011